University of Miami/Jackson Memorial Hospital (Main-Pediatrics)

ANTIBIOTIC SUSCEPTIBILITY REPORT January - December 2015

Data include 1st isolate from patient

T.J. Cleary, PhD (305 585-7851)
O. V. Martinez, PhD (305 585-6508)

		Percent susceptible (*)													
GRAM-NEGATIVE ISOLATES	**No.**	**AMS**	**TZP**	**CAZ**	**CRO**	**FEP(**)**	**ATM**	**ERT**	**MER**	**AN**	**GM**	**TOB**	**LVX**	**TET**	**SXT**
Escherichia coli (***)	151	37	89	87	84	92(94)	86	100	99	100	82	83	70	58	53
Citrobacter freundii	13	/	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns
Citrobacter koseri	1	/	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns
Klebsiella pneumoniae	79	73	85	82	82	93(97)	84	99	99	98	89	87	91	77	80
Enterobacter aerogenes	18	/	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns
Enterobacter cloacae	53	/	86	87	87	96(99)	85	99	99	99	96	94	99	94	90
Serratia marcescens	16	/	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns
Proteus mirabilis	31	83	99	99	97	97(99)	99	99	99	99	97	99	93	/	77
Morganella morganii	4	/	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns
Providencia struartii	1	/	ns	ns	ns	ns	ns	ns	ns	ns	/	/	ns	/	ns
Pseudomonas aeruginosa	68	/	89	82	/	84	77	/	89	99	93	95	86	/	/
Acinetobacter baumannii	16	/	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns
Stenotrophomonas maltophilia	17	/	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns

(*) Clinical Laboratory Standards Institute (CLSI) M100-S26, 2016 breakpoints for antibiotic susceptibility

(**) *Enterobacteriaceae:* cefepime has two dose-dependent susceptibility breakpoints; susceptible at 1g q12 and at (2g q8)

(***) 92% of urinary *Escherichia coli* isolates (n=39) were susceptible to nitrofurantoin

(/) slash indicates that the drug is clinically ineffective or <20% susceptible (Sanford Guide to Antimicrobial Therapy, 2015)

(nd) no antimicrobial susceptibility data available

(ns) statistical significance uncertain due to insufficient number of isolates

		Percent susceptible (*)													
GRAM-POSITIVE ISOLATES	**No.**	**AMP**	**PEN**	**OX**	**CTX**	**CLN**	**GM**	**LVX**	**RIF**	**TET**	**LZD**	**VA**	**SXT**	**ERY**	**DAP**
Enterococcus faecalis	62	97	/	/	/	/	/	89	/	20	99	98	/	/	98
Enterococcus faecium	11	ns	/	/	/	/	/	ns	/	ns	ns	ns	/	ns	nd
Staph aureus MRSA[a]	41	/	/	0	/	81	90	44	98	88	99	98	93	17	98
Staph aureus MSSA[a]	61	/	/	99	/	70	95	92	99	86	99	99	93	59	95
Staphylococcus epidermidis[a]	71	/	/	16	/	33	60	57	96	80	99	96	66	/	96
Staphylococcus haemolyticus[a]	9	/	ns	ns	/	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns
Staphylococcus hominis[a]	4	/	ns	ns	/	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns
Streptococcus agalactiae	4	ns	ns	ns	/	ns	/	ns	/	/	/	ns	ns	ns	/
Streptococcus pneumoniae	3	/	ns	ns	/	ns	/	ns	/	/	ns	ns	ns	ns	ns

(a) S. aureus and coagulase-negative staph (CNS) resistant to oxacillin are resistant to penicillins, cephalosporins and carbapenems
overall MRSA = 40% of all *Staphylococcus aureus* isolates

AMP **AMPICILLIN**
AMS **AMPICILLIN/SULBACTAM**